CLVS Clovis Oncology Inc.
25.32
+1.14 (+5%)
Previous Close
24.18
Open
24.19
Price To Book
5.72
Market Cap
1334663460
Shares
52,711,827
Volume
1,222,246
Short Ratio
Av. Daily Volume
2,295,611
NewsSee all news
- Clovis Oncology to Present at the 8th Annual SVB Leerink Healthcare Conference
- The Zacks Analyst Blog Highlights: Intercept, Gilead, Vertex, Alkermes and Clovis
- Biotech Stock Roundup: ICPT Strong on NASH Drug Data, Collaborations & More
- Is the Options Market Predicting a Spike in Clovis Oncology (CLVS) Stock?
- Alkermes and Clovis Oncology Initiate Research Collaboration to Explore Combination Cancer Therapies
SEC filingsSee all SEC filings
- SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19608456
- SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19606821
- SC 13G - Statement of acquisition of beneficial ownership by individuals 19605866
- SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19601945
- SC 13G - Statement of acquisition of beneficial ownership by individuals 19601227
Drug Information
Drug catalyst information is displayed when you hover over the stage bar graph.
Phase 2 ongoing. Abstract presented at ASCO June 2018.
Opdivo and Rubraca
Castration-resistant prostate cancer (mCRPC)
Phase 3 trial planned.
Opdivo and Rubraca
Triple-negative breast cancers
Phase 3 enrollment has commenced - noted August 8, 2018.
Opdivo and Rubraca ATHENA
Ovarian Cancer - First-line maintenance treatment
Phase 3 trial open for enrollment - February 22, 2017.
Rucaparib - TRITON3
Castration-Resistant Prostate Cancer
Phase 1b/2 trial initiated January 2016
Rociletinib in combination with atezolizumab
EGFR-mutant non-small cell lung cancer
Approval announced April 6, 2018.
Rucaparib ARIEL3
Ovarian cancer patients with a BRCA-like mutation
PDUFA date was June 28, 2016. Company expect CRL. Phase 3 TIGER-3 also terminated.
Rociletinib
Mutant EGFR T790M-positive lung cancer
Development discontinued
Lucitanib
Breast cancer
Approved December 19, 2016. Original PDUFA date under priority review was February 23, 2017.
Rucaparib ARIEL2
Cancer - ovarian second line
Phase 2 initial data presented at ESMO - 44% ORR.
Rucaparib - TRITON2
Castrate-resistant prostate cancer (mCRPC)
Phase 2 ongoing.
Rucaparib - ATLAS
Urothelial carcinoma
ESMO presentation at ESMO October 2018.
Lucitanib
HR+ Her2- metastatic breast cancer
Latest News
- Clovis Oncology to Present at the 8th Annual SVB Leerink Healthcare Conference
- The Zacks Analyst Blog Highlights: Intercept, Gilead, Vertex, Alkermes and Clovis
- Biotech Stock Roundup: ICPT Strong on NASH Drug Data, Collaborations & More
- Is the Options Market Predicting a Spike in Clovis Oncology (CLVS) Stock?
- Alkermes and Clovis Oncology Initiate Research Collaboration to Explore Combination Cancer Therapies
- New Research Coverage Highlights Amicus Therapeutics, Clovis Oncology, YRC Worldwide, FORTERRA INC, Shenandoah Telecommunications, and Basic Energy Services — Consolidated Revenues, Company Growth, and Expectations for 2019
- Clovis Oncology to Announce Fourth Quarter/Fiscal Year 2018 Financial Results and Host Webcast Conference Call on February 26
- See what the IHS Markit Score report has to say about Clovis Oncology Inc.
- Clovis' Rubraca Gets Nod as Maintenance Therapy in Europe
- What's Behind the Biotech ETF Rally to Start 2019?
- Clovis Oncology Announces European Commission Authorization of Rubraca®▼ (rucaparib) Tablets as Maintenance Treatment for Women with Relapsed Ovarian Cancer
- Immunomedics Gets CRL From FDA for Breast Cancer Candidate
- Lilly's 10-Day Sprint For Loxo Could Put Other Names On The Table
- 3 Biotech Stocks That Soared This Week: Are They Buys?
- Implied Volatility Surging for Clovis Oncology (CLVS) Stock Options
- Kill the Cancer Stem Cell, Kill the Cancer: How One Biotech is Hitting Cancer at the Cause
- History Says Pump the Brakes on a Clovis Oncology Stock Rally
SEC Filings
- SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19608456
- SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19606821
- SC 13G - Statement of acquisition of beneficial ownership by individuals 19605866
- SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19601945
- SC 13G - Statement of acquisition of beneficial ownership by individuals 19601227
- SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19600873
- SC 13G - Statement of acquisition of beneficial ownership by individuals 19592332
- SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19583010
- SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19582038
- SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19542446